[Dyslipidemia management in patients with impaired glucose tolerance].
Asano
Michiko
M
Endocrinology, Metabolism and Diabetes, University of Tsukuba.
Yamada
Nobuhiro
N
D000924:Anticholesteremic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001161:Arteriosclerosis / Q000209:etiology / Q000517:prevention & control; D002784:Cholesterol / Q000097:blood; D008076:Cholesterol, HDL / Q000097:blood; D002995:Clofibric Acid / Q000009:adverse effects / Q000627:therapeutic use*; D015118:Eicosapentaenoic Acid / Q000627:therapeutic use; D018149:Glucose Intolerance / Q000150:complications* / Q000503:physiopathology; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D006949:Hyperlipidemias / Q000209:etiology* / Q000628:therapy*; D007333:Insulin Resistance; D008019:Life Style; D008074:Lipoproteins / Q000097:blood; D017202:Myocardial Ischemia / Q000209:etiology / Q000517:prevention & control; D009525:Niacin / Q000627:therapeutic use; D012307:Risk Factors; D014280:Triglycerides / Q000097:blood
D000924:Anticholesteremic Agents; D008076:Cholesterol, HDL; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D008074:Lipoproteins; D014280:Triglycerides; C112017:remnant-like particle cholesterol; D009525:Niacin; D002995:Clofibric Acid; D002784:Cholesterol; D015118:Eicosapentaenoic Acid